Enzalutamide reduces skeletal-related events in men with advanced castration-resistant prostate cancer
the ONA take:
According to a new study published in the journal Lancet Oncology, enzalutamide was found to decrease the risk of skeletal-related events, including radiotherapy to the bone and spinal cord compression, in men with metastatic castration-resistant prostate cancer (mCRPC). In addition, enzalutamide lowered pain and increased quality of life.
In the phase 3 AFFIRM study, patients with mCRPC whose disease progressed on or after docetaxel either took enzalutamide, an androgen receptor, by mouth once daily or placebo. Researchers found that enzalutamide decreased the risk of skeletal-related events by 31% compared with placebo (P=0.0001), and the duration to first skeletal-related event was 16.7 months for patients who took enzalutamide versus 13.3 months for those who took placebo (P=0.0001).
Furthermore, enzalutamide decreased pain severity (P<0.0001) and risk of pain progression (P=0.0018). Patients on enzalutamide experienced health-related quality of life (HRQoL) deterioration after 9.0 months, while those on placebo had HRQoL deterioration in 3.7 months (P<0.0001).
Xtandi (enzalutamide) was initially approved by the U.S. Food and Drug Administration (FDA) in 2012, and the FDA recently approved enzalutamide as first-line therapy for men with mCRPC.
Enzalutamide was found to decrease the risk of skeletal-related events in mCRPC.
Enzalutamide (XTANDI™) reduces the risk of skeletal-related events compared with placebo, as well as reducing pain and increasing quality of life in men with metastatic castration-resistant prostate cancer (mCRPC) according to new results from the AFFIRM study published in Lancet Oncology.
Bone is the most common site of spread in prostate cancer, accounting for about 90% of metastases, resulting in some of the most painful and functionally compromising complications of the disease.
Professor Johann De Bono, Professor of Experimental Cancer Medicine at The Institute of Cancer Research London, and Head of the Drug Development Unit at The Royal Marsden NHS Foundation Trust, comments: "These quality of life data endorse the fact that enzalutamide is a major advance in the treatment of prostate cancer."
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- Atezolizumab Granted FDA Approval for Specific Cases of NSCLC
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- HIIT Improves Cardiorespiratory Fitness in Patients With Resectable NSCLC
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Recurrence Score Appears To Be Driving Personalized Treatment for Breast Cancer
- Smoking-related Cancer Deaths Highest in Southern United States
- Study Suggests More Men With Prostate Cancer Would Choose Active Surveillance if it Were Offered
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|